Related Experiment Video
Updated: Feb 12, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults
Na Zhu1, Claudia Gonzaga-Jauregui1, Carrie L Welch1
1Department of Pediatrics (N.Z., C.W., L.M., U.K., E.B.R., W.K.C.), Herbert Irving Comprehensive Cancer Center (A.S., W.K.C.), and Department of Medicine (E.B.R., W.K.C.), Columbia University Medical Center, Department of Applied Physics and Applied Mathematics (H.Q.), Department of Systems Biology (N.Z., H.Q., Y.S.), and Department of Biomedical Informatics (Y.S.), Columbia University, New York, NY; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY (C.G.-J., A.K.K., J.G.R., J.D.O., A.B., F.D.); Department of Pediatric Cardiology, Children's Hospital Colorado, Denver (D.D.I.); Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN (E.D.A., R.H.); and Division of Human Genetics, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, OH (W.C.N., M.W.P., K.A.L.).
Insights
Genetic analysis reveals TBX4 mutations are more common in pediatric pulmonary arterial hypertension (PAH) patients. De novo variants in novel genes also contribute to pediatric PAH, offering new insights into this rare disease.
Area of Science:
- Genetics
- Pediatrics
- Cardiology
Background:
- Pulmonary arterial hypertension (PAH) is a severe condition involving pulmonary arteriole remodeling and heart failure.
- Pediatric PAH is more heterogeneous and has a worse prognosis than adult PAH.
- The genetic basis of pediatric PAH is less understood than adult familial PAH (FPAH), where BMPR2 mutations are common.
Purpose of the Study:
- To investigate the genetic underpinnings of pediatric-onset PAH.
- To compare the genetic causes of PAH in pediatric and adult patients.
- To identify novel genetic factors contributing to idiopathic PAH (IPAH) in children.
Main Methods:
- Genetic analysis of 155 pediatric and 257 adult PAH patients (FPAH and IPAH).
- Screening for common PAH risk genes followed by exome sequencing for mutation-negative cases.
- Analysis of mutation frequencies, age-of-onset, and de novo variants.
Main Results:
- BMPR2 mutations were found in similar frequencies (≈55% FPAH, 10% IPAH) in both pediatric and adult patients.
- TBX4 mutations were significantly enriched in pediatric IPAH (10/130) compared to adult IPAH (0/178), with earlier age-of-onset.
- De novo variants in novel genes were identified in approximately 19% of pediatric IPAH cases without known mutations.
Conclusions:
- Known PAH risk genes explain a significant portion of FPAH (70-80%) in both age groups.
- TBX4 mutations are a notable genetic cause of pediatric PAH, distinct from adult cases.
- Novel de novo variants likely contribute to a substantial proportion of pediatric IPAH, highlighting the need for further genetic discovery.
Background:
Pulmonary arterial hypertension (PAH) is a rare disease characterized by pulmonary arteriole remodeling, elevated arterial pressure and resistance, and subsequent heart failure. Compared with adult-onset disease, pediatric-onset PAH is more heterogeneous and often associated with worse prognosis. Although BMPR2 mutations underlie ≈70% of adult familial PAH (FPAH) cases, the genetic basis of PAH in children is less understood.
Methods:
We performed genetic analysis of 155 pediatric- and 257 adult-onset PAH patients, including both FPAH and sporadic, idiopathic PAH (IPAH). After screening for 2 common PAH risk genes, mutation-negative FPAH and all IPAH cases were evaluated by exome sequencing.
Results:
We observed similar frequencies of rare, deleterious BMPR2 mutations in pediatric- and adult-onset patients: ≈55% in FPAH and 10% in IPAH patients in both age groups. However, there was significant enrichment of TBX4 mutations in pediatric- compared with adult-onset patients (IPAH: 10/130 pediatric versus 0/178 adult-onset), and TBX4 carriers had younger mean age-of-onset compared with BMPR2 carriers. Mutations in other known PAH risk genes were infrequent in both age groups. Notably, among pediatric IPAH patients without mutations in known risk genes, exome sequencing revealed a 2-fold enrichment of de novo likely gene-damaging and predicted deleterious missense variants.
Conclusions:
Mutations in known PAH risk genes accounted for ≈70% to 80% of FPAH in both age groups, 21% of pediatric-onset IPAH, and 11% of adult-onset IPAH. Rare, predicted deleterious variants in TBX4 are enriched in pediatric patients and de novo variants in novel genes may explain ≈19% of pediatric-onset IPAH cases.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

